Opioid Induced Constipation | Treatment Algorithms: Claims Data Analysis | US | 2022

The drug market for opioid-induced constipation (OIC) is served by a variety of prescription medications, including several agents that are approved for irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) and used off-label. However, many patients turn to over-the-counter (OTC) therapies, keeping drug treatment rates low. As a result, recently approved therapies such as Motegrity and Zelnorm have had difficulty gaining market share. More-established therapies such as Linzess and Movantik continue to secure use in both newly diagnosed and recently treated patients. Persistency and compliance rates are relatively low in this market compared with other indications, highlighting the importance of securing early use.


  • What patient shares do key therapies and brands garner by line of therapy in newly diagnosed OIC patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed OIC patients?
  • How has Linzess been integrated into the treatment algorithm, and what is its source of business?
  • What percentage of OIC patients receive drug therapy within 365 days of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within 365 days of diagnosis?
  • What percentage of OIC patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
  • What are the product-level compliance and persistency rates among drug-treated patients?


Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketer scan accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.

Markets covered: United States

Key companies: Allergan / Ironwood, Synergy Pharma, Takeda / Mallinckrodt, Alfasigma, Takeda, Ardelyx, AstraZeneca / Daiichi Sankyo, Endo Pharma, 

Key drugs: Zelnorm, Motegrity, Linzess, Trulance, Ibsrela, Relistor, Symproic, Movantik, Amitiza, lubiprostone generic, naloxone, stimulant laxatives, osmotic laxatives, dietary fiber supplements

Login to access report